DocGo (DCGO) AI Stock Analysis

• Market Cap: $142.80M
• Dividend Yield: N/A
• Average Volume (3M): 392.88K
• Price to Earnings (P/E): 12.7
• Beta (1Y): 0.89
• Revenue Growth: -41.31%
• EPS Growth: -163.08%
• Country: US
• Employees: 3,404
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.11
• Shares Outstanding: 97,808,136
• 10 Day Avg. Volume: 385,542
• 30 Day Avg. Volume: 392,875
• PEG Ratio: 0.11
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 6.73
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 0.23
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: -8.16
• 1Y Price Target: $3.15
• Price Target Upside: 115.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 54 Neutral
• Price Target: $1.50 ▲(2.74% Upside)

DocGo's overall stock score reflects significant financial challenges, including declining revenue and profitability, and a negative valuation. While technical analysis and earnings call insights show some positive developments, such as operational improvements and cash flow strength, these are overshadowed by the broader financial difficulties and valuation concerns.

Positive Factors

Operational Efficiency

The reduction in SG&A costs reflects improved operational efficiency, which can enhance profitability and provide a competitive edge in the long term.

Cash Flow Improvement

Strong cash flow from operations indicates robust financial health, enabling DocGo to reinvest in growth initiatives and maintain financial stability.

AI Integration

AI integration in operations can lead to increased efficiency and reduced operational costs, positioning DocGo as a tech-forward leader in healthcare services.

Negative Factors

Revenue Decline

The significant revenue decline poses challenges for sustaining growth and profitability, impacting the company's ability to invest in future opportunities.

Negative EBITDA

Negative EBITDA indicates operational inefficiencies and margin pressures, which could hinder DocGo's ability to achieve profitability in the near term.

Declining Profitability

Persistent negative profitability reflects ongoing challenges in cost management and revenue generation, potentially affecting long-term financial health.

DocGo Business Overview & Revenue Model

Company Description

DocGo (DCGO) is a leading provider of mobile health services and innovative healthcare solutions, primarily operating within the telehealth and healthcare logistics sectors. The company specializes in delivering high-quality healthcare services directly to patients at home or in remote locations, leveraging technology to enhance patient care. Its core offerings include on-site medical services, telehealth consultations, and patient transport services, aimed at improving access to care and optimizing healthcare delivery.

How the Company Makes Money

DocGo generates revenue through multiple channels, primarily by billing for its healthcare services provided to patients and healthcare facilities. Key revenue streams include direct payments from patients for telehealth consultations, contracts with hospitals and clinics for on-site medical services, and partnerships with healthcare organizations to provide mobile health solutions. Additionally, the company may receive reimbursements from insurance providers for covered services. Significant partnerships with hospitals and health systems enhance its service offerings and expand its market reach, contributing to overall revenue growth.

DocGo Financial Statement Overview

Summary

DocGo's financial performance is challenged by declining revenue and profitability, with a negative net profit margin and inconsistent cash flow generation. The balance sheet shows moderate leverage but poor returns on equity, indicating inefficiencies.

Income Statement

DocGo's income statement shows significant volatility. The TTM data indicates a negative revenue growth rate of -16.24%, and negative margins across the board, with a net profit margin of -4.20%. Historical data shows fluctuating revenue growth and profitability, with a notable decline in recent periods. The company faces challenges in maintaining stable revenue and profitability.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.20 in the TTM period, indicating manageable leverage. However, the return on equity is negative, suggesting inefficiencies in generating returns from equity. The equity ratio is relatively stable, but the company needs to improve its profitability to enhance balance sheet strength.

Cash Flow

Cash flow analysis reveals a mixed picture. The TTM free cash flow growth is exceptionally high at 48718800.06%, but this is likely due to a low base effect. The operating cash flow to net income ratio is 0.43, indicating some challenges in converting income to cash. The company needs to stabilize its cash flow generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	435.97M	616.56M	624.29M	440.52M	318.72M	94.09M
Gross Profit	25.42T	213.57M	195.38M	154.72M	109.75M	31.35M
EBITDA	-12.50M	45.80M	32.73M	32.40M	28.07M	-9.25M
Net Income	-18.33M	19.99M	6.86M	34.58M	23.74M	-14.36M
Balance Sheet
Total Assets	408.26M	455.62M	490.45M	393.28M	309.60M	100.17M
Cash, Cash Equivalents and Short-Term Investments	104.16M	89.24M	59.29M	157.34M	175.54M	32.42M
Total Debt	60.45M	57.19M	46.50M	19.91M	16.51M	13.89M
Total Liabilities	120.53M	140.44M	185.28M	114.35M	82.55M	33.23M
Stockholders Equity	297.28M	320.92M	300.79M	273.23M	219.58M	55.00M
Cash Flow
Free Cash Flow	81.32M	64.50M	-74.35M	23.37M	-8.60M	-16.97M
Operating Cash Flow	87.18M	70.34M	-64.22M	28.87M	-1.95M	-10.65M
Investing Cash Flow	-34.19M	-10.87M	-29.88M	-38.45M	-8.59M	-6.04M
Financing Cash Flow	-31.11M	-24.15M	1.12M	-6.18M	155.21M	-812.09K

DocGo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCGO, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.52, and below the 200-day MA of 2.61, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.68 is Neutral, neither overbought nor oversold. The STOCH value of 24.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCGO.

DocGo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUNA	69 Neutral	490.71M	7.78	14.44%	―	2.83%	―
TALK	61 Neutral	447.14M	162.96	―	―	17.43%	―
INNV	57 Neutral	686.33M	-21.39	-12.90%	―	11.76%	-42.52%
DCGO	54 Neutral	$142.80M	12.68	-5.98%	―	-41.31%	-163.08%
CYH	53 Neutral	448.38M	-2.13	17.49%	―	0.80%	-95.01%
PIII	48 Neutral	65.33M	-0.21	-178.90%	―	4.20%	-54.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

DocGo Corporate Events

DocGo Holds Annual Stockholders Meeting on June 17

On June 17, 2025, DocGo Inc. held its Annual Meeting of Stockholders, where several key decisions were made. The election of three Class I directors was confirmed, and the compensation of named executive officers was approved on a non-binding basis. However, amendments to the company’s charter regarding corporate opportunities and officer exculpation were not approved. Additionally, the appointment of Urish Popeck & Co., LLC as the independent registered public accounting firm for 2025 was ratified.

DocGo Extends Share Repurchase Program to December

On June 12, 2025, DocGo Inc. announced an extension of its share repurchase program’s expiration date from June 30, 2025, to December 31, 2025, allowing the company to continue purchasing up to $26 million in common stock. This extension provides the company with flexibility to repurchase shares based on market conditions and other factors, potentially impacting its stock value and benefiting shareholders.